Beranda › Atrofi Otot Tulang Belakang › Michigan
Uji klinis Atrofi Otot Tulang Belakang di Michigan
6 studi untuk Atrofi Otot Tulang Belakang mencari peserta di lokasi di Michigan.
Kota di Michigan
Teks studi resmi (Bahasa Inggris)
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene Therapy
- Helen DeVos Children's Hospital at Spectrum Health, Grand Rapids
Menerima pesertaFase 4
3 Months – 24 Months · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT05861986A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy
- Helen DeVos Children's Hospital at Spectrum Health, Grand Rapids
Menerima pesertaFase 2
Hingga usia 2 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT07047144A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene Therapy
- Helen DeVos Children's Hospital at Spectrum Health, Grand Rapids
Menerima pesertaFase 4
3 Months – 24 Months · Semua jenis kelamin · Diperbarui 10 Sep 2026 · NCT05861999A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK)
- Helen DeVos Children's Hospita, Grand Rapids
Menerima pesertaFase 1
Usia 3 ke atas · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT06555419Study of an Intrathecal Port and Catheter System for Subjects With Spinal Muscular Atrophy
- Helen DeVos Children's Hospital, Grand Rapids
Menerima peserta
Usia 3 ke atas · Semua jenis kelamin · Diperbarui 19 Agu 2026 · NCT05866419ALS/MND Natural History Study Data Repository
- Henry Ford Health System, Detroit
- Trinity Health Michigan, Grand Rapids
Menerima pesertaStudi observasional
Usia 18 hingga 90 · Semua jenis kelamin · Diperbarui 20 Mei 2026 · NCT05966038Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.